Molecule to Market: Inside the outsourcing space

The entrepreneurial scientist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Alok Tayi, Vice President of Life Sciences at Egnyte and the founder of the Biotech 2050 podcast. Alok has a very impressive academic and entrepreneurial background in life sciences, before running the fast-growing life science division at Egnyte, he was a Co-Founder of PreScouter and TetraScience, raising millions along the way. Having completed a postdoctoral fellowship at Harvard University, he has also been published in Forbes and Nature.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole loaf more) with Alok, covering how he founded, built and scaled two life science software companies… and then did it all over again as a vertical of a larger organisation. Alok shares the lessons he learned while raising millions in VC capital and the value of building relationships early on. He explains how CDMOs and CROs can become more strategic with biotech clients by seeing themselves as data and knowhow specialists. Finally, Raman and Alok discuss the journey of the contract services space and how the landscape has shifted from a largely transactional rigid business to becoming the foundational bedrock of the life science domain. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The sales guru

In this episode of Molecule to Market, we do things a little differently with an experimental episode. You’ll go inside the outsourcing space of the global drug development sector with the best-selling sales author, Ian Altman. 

 

Ian started, sold, and grew his prior companies from zero to over one billion dollars in value. He’s a co-author of the bestseller, Same Side Selling, now in its second edition. He is the author of hundreds of articles on Forbes and Inc. Ian is recognized as one of the world’s Top 30 Global Gurus on Sales, and his Same Side Selling Academy is ranked in the top 5 globally for Sales Development Programs.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Ian Altman discussing “becoming a magnet for your client’s problem” while also making sure the client has a problem worth solving. Ian speaks on the importance of role-playing, practising and rehearsing sales scenarios. He explains the need to aim for the ‘engage’ level with potential clients in order to secure the next pharma or biotech deal. Lastly, Ian explains the importance of understanding your client’s Elevator Rant and the emotion and impact of not solving their issue.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Marathons. Wine. And 30 years in healthcare.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marco Chiado’ Piat, President, at Terumo Pharmaceutical Solutions part of Terumo. Marco has worked in the pharma and healthcare sector since the early 1990s. His impressive experience has included eight years at McKinsey before he founded a VC business. He then had several senior roles at medical device specialist LivaNova before joining Terumo Pharmaceutical Solutions in 2017, where he has risen to the top. If that was not enough, he’s an accomplished marathon runner and runs a winery in Northern Italy with his brother.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest Marco Chiado’ Piat covering the importance of passion, curiosity and simply liking what you do as important pillars for serving your purpose. Marco explains how running marathons and ultra marathons has not only helped train his body for resistance but has also trained his mind for resilience. He tells Raman of the unrest Covid has caused medical device companies, and the apparent value of long term thinking that is inherent in the pharmaceutical sector. Marco closes with the importance of being ready for the unknown and unforeseen by having an ‘agility muscle’ ready to flex into action.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The industry guru

In this one hour special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jim Miller. If you’ve worked in the bio and pharmaceutical CDMO space for a few years, then there’s a very good chance you will know my guest today. Jim is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jim, covering how his husband & wife start-up business helped put the industry on the map while providing CMOs/CDMOs with invaluable drug pipeline intel. He explains how CDMOs have enabled the success of the explosion of emerging biopharma in the last 10 years, helping them turn IP into product. He also gives his expert take on the changing role of CDMOs in Asia and whether we will see any APIs bounce back to North America and Europe. Lastly he covers the robustness of the market post Covid-19 and whether to expect to see a financial dip or not.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

10 Trends for 2021

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with... Raman Sehgal, founder of ramarketing and the Molecule to Market podcast.

Your host, Raman shares ten trends that he expects to see in 2021 and beyond based on themes from podcast interviews and expert insights gathered in 2020.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The CDMO Disrupter

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tia Lyles-Williams, CEO of LucasPye Bio. Tia is the first African-American Queer Woman to own & lead a Biopharma Large-Scale Manufacturing Company in the US. She has spent 20 years in the industry formerly working for the U.S. Federal Government, Big Pharma and Small Biotech Companies, before setting up her own CDMO. Tia is not only highly knowledgeable about the biotechnology sector but she works hard on helping economic development in underserved communities.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tia, covering how equality and diversity in the pharma and biotech space is no better now than it was 20 years ago, which is being compounded by Covid-19. She describes the challenges of fundraising and getting a biotech CDMO built and off the ground in an economically underserved community in Philadelphia. She stresses the importance in young people taking their education and experience into their own hands and going the extra mile to unlock new opportunities, “don’t ask permission to lead” she says. Lastly, Tia speaks on creating a new breed of CDMOs, organizations that are highly digital, leaner, faster, cheaper, and more transparent with a social conscience. She also wants to put Pennsylvania on the map as the next major global life science biotech hub.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The biologic CDMO growth guy

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Roger Lias, Chief Executive Officer at Stelis Biopharma. A fellow-Brit, Roger is a graduate of the University of Southampton. He also holds a PhD in Biotechnology from the University of Cambridge. His experience of the biopharma CDMO space in particular spans over 30 years including roles with the likes of Lonza, Diosynth, KBI Biopharma, Cytovance Biologics, Eden Biodesign, Allergen and Avid Bioservices and of course, Stelis. During the early part of his career, he moved to North America and now lives in California. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain (and a whole load more) with Roger, covering an incredible 30 year journey at the heart of the biologic drug development explosion, including roles with the 'who’s who' of large molecule CDMOs. Roger speaks about what it was like creating a biologics CMO from the ground-up in the 90s with no obvious market. Raman and Roger discuss the value of being curious, energetic, open-minded and simply building relationships as the pillars to a long, successful career in the outsourcing space. Lastly, Roger speaks on the trend towards a closer collaboration between CDMO competitors, after all, nobody can do everything.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Leading M&A at a top-5 global CDMO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Mark Quick, Executive Vice President, Corporate Development at Recipharm. In the decade that Mark and Raman have known each other, Mark has risen from a BD role in a small Swedish CMO, to becoming one of the key leaders in a business that has transitioned into becoming one of the top global CDMOs, where Mark has spearheaded the M&A deals. A graduate in Industrial Studies, Mark also did an MBA before joining Recipharm in 2006. 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guest (and a whole loaf more) with Mark as he explains what it’s been like growing a company from 600 - 9000 people, lifting the lid on CDMO M&A deals (having done 20+ transactions over the past 14 years), who gets involved, red flags to look out for and when you just know it’s a good fit. Mark explains how investing in relationships, embracing diversity and being open to new connections has helped him propel his career in the outsourcing space. He speaks about COVID-19 and how it has impacted a global CDMO in its different phases, including the operational impact of having sites in India and Italy. Lastly, Mark and Raman discuss continued consolidation in the sector and the increasing demand for sterile drug products with supply constraints and COVID-19 vaccines jumping the line.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

The virotherapy virtuoso

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Stefan Beyer, President and Managing Director at Vibalogics and Tom Hochuli, Chief Executive Officer at Vibalogics. Who is this dynamic duo you ask? Stefan has spent the bulk of his career in the vaccines and biologics space. He has been head of Vibalogics for almost 13 years, steering the company from a local startup, to global CDMO and world leader in the production of virotherapy products and oncolytic vaccines. Tom has over 25 years experience in the sector and prior to Vibalogics, he headed the cell and gene therapy operations for Lonza Houston. Today, Tom is responsible for Vibalogics’ U.S. expansion plans as the company sets its sights on developing a late phase and commercial virus manufacturing facility on the East Coast, U.S.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with guests Stefan and Tom, covering the boom in virotherapy capabilities such as oncolytic viruses, viral vector gene therapies and viral vector vaccines over the past decade. Tom discusses the lessons he’s learned from being a platoon leader in the US Army to leading teams in business. Tom and Stefan explain how as a leader, it is important to have an open mind when it comes to exploring new opportunities and ideas and accepting failure as a part of success and learning. Lastly we explore the short-term impact that Covid-19 has had on delaying promising pipelines and compounds currently in clinical trials. We look ahead to the longer-term impact it will have on refocusing drug developers’ attention on the need for vaccines, and being better prepared in the case of an infectious outbreak. 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.

Roundtable: Collaboration and driving efficiency

In this special episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with host  Raman Sehgal, Founder & Global President at ramarketing, Laura Child, CRO Sector Lead at ramarketing, Dexter Tjoa, Chief Executive Officer at Tjoapack, Erik Haeffler, VP Manufacturing Services & Head of Sustainability at Recipharm AB, John Ross, President at Mayne Pharma and Metrics Contract Services, and Mark Emalfarb, CEO, Board Member and Founder at Dyadic International, Inc.

During this discussion we will explore two angles to driving efficiency, diversification vs. development of specialism. Emerging trends include the move to manufacture multiple technologies under one roof, at the other end of the scale we see companies staying true to original areas of expertise in order to refine and grow.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also love a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international content, design and digital agency that helps companies get noticed, raise profile and generate leads in life sciences.